P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) restrict the brain penetration of the Janus family of tyrosine kinase (JAK) inhibitor CYT387

被引：0
|
作者：
Durmus, Selvi [1 ]
Xu, Ning [2 ]
Sparidans, Rolf W. [3 ]
Wagenaar, Els [1 ]
Beijnen, Jos H. [4 ]
Schinkel, Alfred H. [1 ]
机构：
[1] Netherlands Canc Inst, Div Mol Oncol, Amsterdam, Netherlands
[2] China Japan Union Hosp, Changchun, Peoples R China
[3] Univ Utrecht, Fac Sci, Dept Pharmaceut Sci, Utrecht, Netherlands
[4] Slotervaart Hosp, Dept Pharm & Pharmacol, Amsterdam, Netherlands
来源：
FASEB JOURNAL | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
1103.1
引用
收藏
页数：1
相关论文
共 50 条
  • [1] P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387
    Durmus, S.
    Xu, N.
    Sparidans, R. W.
    Wagenaar, E.
    Beijnen, J. H.
    Schinkel, A. H.
    PHARMACOLOGICAL RESEARCH, 2013, 76 : 9 - 16
  • [2] Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)
    Xu, Yanyan
    Egido, Estefania
    Li-Blatter, Xiaochun
    Mueller, Rita
    Merino, Gracia
    Berneche, Simon
    Seelig, Anna
    BIOCHEMISTRY, 2015, 54 (40) : 6195 - 6206
  • [3] Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice
    Wang, Jing
    Bruin, Maaike A. C.
    Gan, Changpei
    Lebre, Maria C.
    Rosing, Hilde
    Beijnen, Jos H.
    Schinkel, Alfred H.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 581
  • [4] Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)
    Hofman, Jakub
    Kucera, Radim
    Cihalova, Daniela
    Klimes, Jiri
    Ceckova, Martina
    Staud, Frantisek
    PLOS ONE, 2013, 8 (10):
  • [5] P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib Metabolite N-Desethyl Sunitinib
    Tang, Seng Chuan
    Lankheet, Nienke A. G.
    Poller, Birk
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 341 (01): : 164 - 173
  • [6] Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation
    van Hoppe, Stephanie
    Sparidans, Rolf W.
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    PHARMACOLOGICAL RESEARCH, 2017, 120 : 43 - 50
  • [7] Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux
    Agarwal, Sagar
    Sane, Ramola
    Gallardo, Jose L.
    Ohlfest, John R.
    Elmquist, William F.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (01): : 147 - 155
  • [8] Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
    Tang, Seng Chuan
    Nguyen, Luan N.
    Sparidans, Rolf W.
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (06) : 1484 - 1494
  • [9] Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)
    Selvi Durmus
    Rolf W. Sparidans
    Anita van Esch
    Els Wagenaar
    Jos H. Beijnen
    Alfred H. Schinkel
    Pharmaceutical Research, 2015, 32 : 37 - 46
  • [10] Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)
    Durmus, Selvi
    Sparidans, Rolf W.
    van Esch, Anita
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    PHARMACEUTICAL RESEARCH, 2015, 32 (01) : 37 - 46
12345